Roland Kratzer, et al. AASLD & Hepatology, October 2016 – DOI: 10.1002/hep.28800 Download the poster here Poster Presentation
Transgene presents preclinical results of TG1050, an HBV-targeted immunotherapy, at AASLD 2016 Liver Meeting
First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients
Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee
20160721 – Safety TG1050 EN Vdef
Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection
20151103 TG1050 FINAL VERSION US
Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.
Ophelie Godon, et al. Vaccine. 2015 Aug 26;33(36):4548-53 – Download the article Publication
TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models
Karine Lélu, et al. EASL Liver Congress 2015, Vienna-23th April 2015 Download the poster here Poster Presentation
Transgene Presents New Data with TG1050, an Immunotherapy being Developed to Treat Chronic Hepatitis B, at The International Liver Congress™ 2015
20150423 – US – EASL2015 TG1050
Viral hepatitis: HBV cure—can we pin our hopes on immunotherapy ?
Hung-Chih Yang, et al. Nature Reviews Gastroenterology & Hepatology (2015) doi:10.1038/nrgastro.2015.8 – Download the article Publication
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
Martin P, Dubois, et al. Gut. 2014 Nov 26, doi: 10.1136/gutjnl-2014-308041 – Download the article Publication